(Q42538403)

1 November 2017

Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories (English)

1 reference

1 November 2017

1 reference

P Sjøgren

1

1 reference

1 November 2017

L P Thunedborg

2

1 reference

1 November 2017

L Christrup

3

1 reference

1 November 2017

S H Hansen

4

1 reference

1 November 2017

J Franks

5

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

Acta Anaesthesiologica Scandinavica

1 November 2017

1 reference

1 November 2017

42

1 reference

1 November 2017

9

1 reference

1 November 2017

1070-1075

1 reference

Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine

1 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Myoclonic seizure activity with chronic high-dose spinal opioid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine-3-glucuronide--a potent antagonist of morphine analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine-3-glucuronide: silent regulator of morphine actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine, morphine-6-glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal morphine administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-6576.1998.TB05378.X

10.1111/J.1399-6576.1998.TB05378.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference